NOVEL TRIAZINE DERIVATIVE
    2.
    发明申请
    NOVEL TRIAZINE DERIVATIVE 审中-公开
    新的TRIAZINE DERIVATIVE

    公开(公告)号:US20150011751A1

    公开(公告)日:2015-01-08

    申请号:US14383860

    申请日:2013-03-07

    摘要: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturated 5- to 6-membered ring, thereby forming a multiply fused ring, or a pharmaceutically acceptable salt thereof.

    摘要翻译: 提供由下式(I)表示的新型三嗪衍生物:由下式(I)表示的三嗪衍生物:其中R1表示取代或未取代的芳基,取代或未取代的杂环,取代或未取代的杂环稠合 环或取代或未取代的炔基,R 2表示氢原子,卤素原子,取代或未取代的低级烷基或取代或未取代的烷氧基,R 3表示取代或未取代的芳基,取代或未取代的杂环 环或取代或未取代的杂环稠合环,R4表示氢原子,取代或未取代的低级烷基,取代或未取代的烷氧基,取代或未取代的氨基或卤素原子,R5表示氢原子 ,取代或未取代的低级烷基,或R 1和R 5可以组合形成饱和的o r不饱和5-至6-元环,从而形成多稠环,或其药学上可接受的盐。

    Pyrimidine derivative having antimalarial activity

    公开(公告)号:US10538521B2

    公开(公告)日:2020-01-21

    申请号:US16344471

    申请日:2017-10-25

    摘要: The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.

    NOVEL BICYCLIC THIAZOLE COMPOUNDS
    5.
    发明申请
    NOVEL BICYCLIC THIAZOLE COMPOUNDS 有权
    新型双环噻唑化合物

    公开(公告)号:US20150133656A1

    公开(公告)日:2015-05-14

    申请号:US14403071

    申请日:2013-05-22

    摘要: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明涉及抑制Traf2-和Nck相互作用激酶(TNIK)的新型双环噻唑化合物,并且因此可用作给予癌症患者的TNIK抑制剂,特别是用于固体癌症患者如结肠直肠癌,胰腺癌, 小细胞肺癌,前列腺癌或乳腺癌。 二环噻唑化合物由下式(I)表示。 (其中R1,R2,R3和Q如说明书中所定义)或其药学上可接受的盐。

    Furanone derivative
    6.
    再颁专利

    公开(公告)号:USRE48140E1

    公开(公告)日:2020-08-04

    申请号:US15967323

    申请日:2018-04-30

    摘要: To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I): wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents —COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

    Bicyclic thiazole compounds
    8.
    发明授权
    Bicyclic thiazole compounds 有权
    双环噻唑化合物

    公开(公告)号:US09102637B2

    公开(公告)日:2015-08-11

    申请号:US14403071

    申请日:2013-05-22

    摘要: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明涉及抑制Traf2-和Nck相互作用激酶(TNIK)的新型双环噻唑化合物,并且因此可用作给予癌症患者的TNIK抑制剂,特别是用于固体癌症患者如结肠直肠癌,胰腺癌, 小细胞肺癌,前列腺癌或乳腺癌。 二环噻唑化合物由下式(I)表示。 (其中R1,R2,R3和Q如说明书中所定义)或其药学上可接受的盐。